Clinical Studies, Review Extensions, Appointments, and Conference Schedules - Analyst Notes on Karyopharm, Orexigen, INSYS, bluebird bio and AMAG Pharmaceuticals

NEW YORK, June 18, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Orexigen Therapeutics, Inc. (NASDAQ: OREX), INSYS Therapeutics, Inc. (NASDAQ: INSY), bluebird bio, Inc. (NASDAQ: BLUE) and AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3825-100free.

--
Karyopharm Therapeutics, Inc. Analyst Notes
On June 9, 2014, Karyopharm Therapeutics, Inc. (Karyopharm) announced the commencement of a Phase 2 trial, referred to as the SHIP (Selinexor in Hormone Refractory Indications in Prostate Cancer) study, of the Company's oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with metastatic hormone-refractory prostate cancer (HRPC). Dr. Sharon Shacham, Company's Founder, President and Chief Scientific Officer, commented, "We recently presented data at ASCO showing an 88% disease control rate, meaning stable disease or better, in eight evaluable patients with heavily pretreated prostate cancer. These patients were treated in our Phase 1 clinical trial of Selinexor in advanced or metastatic solid tumors. As a result of this encouraging data, we have initiated the SHIP Study, a Phase 2 study to further evaluate Selinexor's potential in patients with treatment-resistant prostate cancer." The full analyst notes on Karyopharm are available to download free of charge at:

http://www.analystsreview.com/Jun-18-2014/KPTI/report.pdf

--
Orexigen Therapeutics, Inc. Analyst Notes
On June 11, 2014, Orexigen Therapeutics, Inc. (Orexigen) announced that the United States Food and Drug Administration (FDA) has extended its review of the Company's resubmitted New Drug Application (NDA) for NB32 - its investigational medication being evaluated for weight loss. The Company informed that the new Prescription Drug User Fee Act (PDUFA) action date is September 11, 2014. According to Orexigen, the FDA has indicated that the review has been extended to reach agreement on the post-marketing obligation regarding the previously agreed upon evaluation of cardiovascular outcomes for NB32. Orexigen CEO, Michael Narachi, stated, "We are working expeditiously with the FDA to finalize the review. We are encouraged by the high level of engagement with the FDA, and are confident that we can reach agreement on the remaining post-marketing obligation." The full analyst notes on Orexigen are available to download free of charge at:

http://www.analystsreview.com/Jun-18-2014/OREX/report.pdf

--
INSYS Therapeutics, Inc. Analyst Notes
On June 10, 2014, INSYS Therapeutics, Inc. (INSYS) announced that it will present on June 24-25, 2014 at the 9th Annual JMP Securities Healthcare Conference at the Westin New York Grand Central. According to the Company, INSYS President and CEO, Michael L. Babich, along with CFO Darryl Baker, will host the presentation on June 25, 2014, at 11:30 a.m. EDT. A live audio webcast of the presentation can be accessed through INSYS' website, where a replay will also be available for 30 days after the initial presentation. The full analyst notes on INSYS are available to download free of charge at:

http://www.analystsreview.com/Jun-18-2014/INSY/report.pdf

--
bluebird bio, Inc. Analyst Notes
On June 13, 2014, bluebird bio, Inc.'s (bluebird bio) stock went up by 3.24%, closing the day at $26.09. For the past three-day trading period, Company's stock reflected an increase of 3.66% compared to the Nasdaq Composite which went down by 0.63% during the same trading period. The full analyst notes on bluebird bio are available to download free of charge at:

http://www.analystsreview.com/Jun-18-2014/BLUE/report.pdf

--
AMAG Pharmaceuticals, Inc. Analyst Notes
On June 11, 2014, AMAG Pharmaceuticals, Inc. (AMAG Pharmaceuticals) announced the appointment of Melissa Bradford Klug, as Senior Vice President of Business Development and Strategy. According to the Company, Klug will report directly to Executive Vice President and Chief Operating Officer, Frank Thomas, whose role will be expanded to include corporate development. Commenting on the appointment, Thomas, stated, "We are pleased to welcome Melissa to AMAG as we continue the work to broaden our portfolio and build a diversified, multi-product specialty company. We have a number of active potential transactions underway and so she joins us at a very exciting time. Melissa's proven ability to lead a team in developing and executing strategic transactions on a global scale, combined with her deep industry knowledge, will be a tremendous asset to AMAG and our shareholders." The full analyst notes on AMAG Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/Jun-18-2014/AMAG/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review